Cyr61/CCN1 Signaling and Pancreatic Cancer
Author Information
Author(s): Haque Inamul, Mehta Smita, Majumder Monami, Dhar Kakali, De Archana, McGregor Douglas, Van Veldhuizen Peter J, Banerjee Sushanta K, Banerjee Snigdha
Primary Institution: Cancer Research Unit, Veterans Affairs Medical Center, Kansas City, MO
Hypothesis
Cyr61/CCN1 plays a critical role in pancreatic carcinogenesis through the induction of epithelial-mesenchymal transition (EMT) and stemness.
Conclusion
Cyr61/CCN1 is involved in pancreatic carcinogenesis and may serve as a potential therapeutic target.
Supporting Evidence
- 81% of pancreatic cancer specimens showed over-expression of Cyr61 mRNA compared to adjacent normal samples.
- 85% of PDAC samples were Cyr61 positive, with higher levels in advanced disease.
- Cyr61 silencing reduced aggressive behaviors in pancreatic cancer cells.
- Addition of Cyr61 protein enhanced EMT and stemness in less aggressive cancer cells.
- Cyr61 was found to be critical for the tumor-initiating capability of pancreatic cancer stem cells.
Takeaway
Cyr61 helps cancer cells change shape and become more aggressive, which makes pancreatic cancer harder to treat.
Methodology
The study involved evaluating Cyr61 expression in pancreatic cancer samples and cell lines, silencing Cyr61, and assessing its effects on cell behavior and migration.
Potential Biases
Potential bias in sample selection and the interpretation of results from animal models.
Limitations
The study primarily focused on in vitro and xenograft models, which may not fully replicate human disease.
Participant Demographics
Human pancreatic adenocarcinoma samples were used, with a focus on high-grade tumors.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website